Understanding Retinal vein occlusion
A central occlusion affects drainage from much of the retina; a branch occlusion affects a smaller venous territory. The visual result varies with the area involved, macular swelling and the degree of impaired circulation, called ischemia. The name alone does not determine an individual prognosis. [1] [2] [3]
Treatment commonly addresses complications rather than physically removing a retinal clot. Anti-VEGF injections can reduce leakage and swelling, while surveillance detects abnormal new vessels that may bleed or raise pressure. A better scan does not automatically mean all ischemic risk has disappeared. [3] [4]
One condition. Different experiences.
Explore different selected symptom features, then read how they may vary. These examples are not stages or a clinical test.
Original VisualSim schematic illustrations, informed by the cited clinical descriptions. These are not study figures, patient recordings or validated severity levels.
Painless blur
Vision may change abruptly or become blurred over a shorter period, often in one eye. Some small branch occlusions are noticed less readily, and the other eye can conceal changes. [1] [2]
Central distortion or reduced detail
Macular edema can make reading difficult or lines look wavy. Ischemia can also limit vision, so reducing fluid does not guarantee that all missing detail returns. [3] [4]
Floaters or later discomfort
Bleeding can produce floaters or haze; abnormal vessels and pressure complications can cause a painful red eye. These changes require clinical assessment rather than assuming they are ordinary injection or aging effects. [1] [2] [3]
Drainage, swelling and abnormal vessels
Original teaching schematic; central and branch territory and individual severity vary. [1] [2] [3]
Original VisualSim teaching diagram · © VisualSim. Clinical basis in linked sources; not a published study figure. Image provenance.- Drainage problem
A blocked vein disrupts retinal circulation.
- Macular effect
Leakage can cause central edema and reduce detail.
- Separate surveillance
Ischemia can drive new vessels and pressure complications even beyond the central scan.
What is happening—and what remains uncertain
Blocked venous drainage increases pressure and leakage in retinal vessels, causing hemorrhage and edema. Reduced oxygen supply can increase VEGF signaling, linking impaired circulation with both leakage and abnormal new vessel growth. [1] [2] [3]
Central and hemiretinal forms have a greater concern for iris or angle neovascularization than many branch occlusions. New vessels can obstruct the drainage angle and cause neovascular glaucoma. Monitoring therefore includes the front of the eye and pressure as well as OCT of the macula. [3]
What can look similar?
Retinal artery occlusion
An artery occlusion is a different circulation emergency and may require a stroke pathway. A person with sudden loss should seek urgent assessment rather than deciding at home that it must be a vein because a previous episode was one. [3] [4]
Similar-looking symptoms can have different causes. A matching picture cannot establish a diagnosis.
What an assessment may involve
- Define the territory and complicationsA dilated examination identifies central, branch or hemiretinal involvement, bleeding and abnormal vessels. Acuity and symptoms are interpreted with the retinal findings; a hemorrhagic photograph is not the person’s visual-field map. [1] [2] [3]
- OCT and circulation imagingOCT quantifies macular fluid, while fluorescein angiography or selected OCT angiography helps assess circulation and leakage. Ask whether the visual limitation is mainly edema, ischemia, structural damage or a combination. [3] [4]
- Systemic review and ongoing checksThe eye team coordinates relevant blood-pressure, glucose, lipid and other assessment with primary care. Broad thrombophilia testing is not automatically useful in every isolated RVO; younger or atypical cases need individualized consideration. Follow-up also checks iris/angle vessels and pressure. [3] [4]
What may help—and what is still being studied
Treat visually relevant macular edema
Anti-VEGF agents are first-line options for many eyes with RVO-related edema. Treatment can need repeated visits and adjustments; drug approval, cost, off-label use and actual response should be discussed openly. Noninferiority on one trial endpoint is not proof of identical performance in every patient. [3] [5] [6]
Address other complications
Steroid implants may be selected but carry cataract and pressure risks. Retinal laser has roles in neovascular complications and selected branch-occlusion circumstances. The goal of a laser for abnormal new vessels differs from an injection aimed at central swelling. [3] [4]
Medical risk management without self-prescribing
Manage relevant health conditions with the appropriate clinician. Evidence does not support routinely starting an anticoagulant or antiplatelet solely to treat an isolated RVO; do not stop one prescribed for another reason. Continued monitoring may be needed after fluid improves or injections are paused. [3] [4]
What this can mean for daily life
Make repeated visits workable
Ask about transport, scheduling, funding and the contact for a missed appointment. Treatment burden is real and should be discussed before missed visits allow complications to go unchecked. [4] [7]
Use accessible reading formats
Reflowed text, magnification and audio can reduce the effort of central tasks. Rehabilitation can help with persistent loss even while the retinal service continues active treatment. [7] [8]
Bring a clearer description to your appointment
Choose the questions you want to discuss. These choices stay in this page’s memory.
Research, with the context left in
Selected studies and guidance, with their populations and limitations. These are curated educational summaries, not a complete systematic review or a formal evidence rating.
AAO Retinal Vein Occlusions Preferred Practice Pattern
Emphasizes anti-VEGF treatment for edema and surveillance for ischemia-related neovascular complications, with different risks across RVO types. [3]
Limits and applicability: Guideline literature cutoff and regional availability limit claims about every newer product; individual acuity and circulation remain important.
SCORE2: bevacizumab versus aflibercept
Bevacizumab met the predefined noninferiority criterion for six-month acuity compared with aflibercept. [5]
Limits and applicability: Not a branch-RVO trial or proof of long-term equivalence under less frequent care. Bevacizumab use is off-label in relevant jurisdictions and rare harms need broader evidence.
BALATON and COMINO
Faricimab was noninferior to aflibercept for 24-week acuity gains during monthly dosing, with different leakage findings. [6]
Limits and applicability: The randomized comparison does not prove superior vision or long-term durability. Later extension analyses switched all participants to faricimab and are not a continuing head-to-head comparison.
Questions researchers still need to answer
- Which markers predict when injection intervals can safely extend while maintaining useful vision?
- How can follow-up better prevent neovascular complications and reduce access burdens in high-risk eyes?
Trusted places to go next
Selected clinical references, research, practical support and ways to connect. Official pages checked 24 October 2026; each entry explains its scope and region.
Macular Society — retinal vein occlusion
Condition information plus advice, counseling and peer-support routes.
Connections listed by the organization.
ASRS — central retinal vein occlusion
Explains central occlusion, swelling and neovascular risks; links to specialist resources.
ASRS — branch retinal vein occlusion
Separate explanation of branch disease and its assessment and treatment.
RNIB — practical sight-loss support
Access technology, work and daily-living support for ongoing sight difficulties.
Connections listed by the organization.
Questions you may still have
Is an injection dissolving the clot?
Anti-VEGF treatment mainly reduces a signaling pathway involved in leakage and swelling; it is not a mechanical clot-removal procedure. [3]
Will a dry OCT mean I no longer need checks?
Not necessarily. Circulation and abnormal new vessel risks can remain, especially in ischemic central disease. Agree a monitoring plan even if injections are paused. [3] [4]
Should I take aspirin to prevent another blockage?
Do not start or stop it on this page’s advice. Routine use solely for isolated RVO lacks strong supporting evidence, while another medical indication may require it. Discuss your actual health risks with the prescriber. [4]
Sources, image credits and review status
Compiled by VisualSim from clinical references and published research. Sources checked 24 October 2026. Independent clinical review has not been recorded; no named clinical reviewer or clinical validation is claimed. Research evidence and its limitations are linked below.
- ASRS — Central Retinal Vein Occlusion (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - ASRS — Branch Retinal Vein Occlusion (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - Kovach et al., AAO — Retinal Vein Occlusions Preferred Practice Pattern (2025; guideline).
Indexed full clinical recommendations and treatment/follow-up sections read; direct client 403. Publication2025, not summary-site update2026.
Checked 2026-10-24 · Full text checked - Nicholson et al., RCOphth — RVO guideline executive summary (2022; guideline).
Indexed clinical and systemic-investigation text read; direct PMC client challenged. Current organizational listing checked; review-due date does not equal new edition.
Checked 2026-10-24 · Full text checked - Scott et al. — SCORE2 randomized clinical trial (2017; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Tadayoni et al. — BALATON and COMINO 24-week results (2024; trial).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Abstract/indexed material checked; complete full-text review not claimed - Macular Society — Retinal vein occlusion (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - RNIB — practical support (n.d.; institution).
Relevant page content and scope checked; source verification is not independent clinical review.
Checked 2026-10-24 · Public page checked - NHS — Vision loss (n.d.; institution).
Official sudden sight-loss/severe pain emergency versus other urgent visual-change guidance checked; local service routes vary internationally.
Checked 2026-10-24 · Public page checked
The simulator helps people communicate an experience. It cannot diagnose a condition, measure a visual field, or establish that someone is safe to drive.